Viking Therapeutics is a biotech company that has been generating a lot of buzz in the investment world, despite not yet bringing in revenue. The question on many investors' minds is whether or not Viking Therapeutics is worth buying even though it is a pre-revenue company.


While it can be risky to invest in a company that is not yet generating revenue, there are several reasons why Viking Therapeutics may still be a good investment. Firstly, Viking Therapeutics has a promising pipeline of drug candidates that are designed to treat a range of metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH) and diabetes. These are areas of high unmet medical need, and if Viking Therapeutics is able to bring a successful drug to market, the potential for revenue generation could be significant.


Additionally, Viking Therapeutics has a strong management team with extensive experience in the biotech industry. The company's leadership has a track record of success in developing and commercializing new drugs, which bodes well for the future success of Viking Therapeutics.


Furthermore, Viking Therapeutics has established partnerships with larger pharmaceutical companies, including Johnson & Johnson, which can provide the company with additional resources and expertise to help advance its drug candidates through clinical trials and towards commercialization.


Of course, investing in any pre-revenue company comes with risks, and there is no guarantee of success. However, for investors who are willing to take on some risk in exchange for the potential for significant returns, Viking Therapeutics could be a compelling investment opportunity.

In conclusion, while investing in a pre-revenue biotech company like Viking Therapeutics may not be suitable for everyone, for those who are willing to take the risk, the potential rewards could be substantial. With a promising pipeline of drug candidates, a strong management team, and strategic partnerships in place, Viking Therapeutics may indeed be worth considering as a part of a diversified investment portfolio.